Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
about
Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingPotential therapeutic targets for neurokinin-1 receptor antagonistsFosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomitingPharmacokinetic evaluation of fosaprepitant dimeglumineAprepitant and fosaprepitant: a 10-year review of efficacy and safetyAprepitant--a novel NK1-receptor antagonist.Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.Chemotherapy-related nausea and vomiting - past reflections, present practice and future management.Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.5-HT3 receptor antagonists for prevention of late acute-onset emesis.Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.Aprepitant (EMEND): the role of substance P in nausea and vomiting.Emerging drugs for chemotherapy-induced emesis.Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitantSafety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.Anti-emetic therapy in cancer chemotherapy: current status.Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.Preparation and pharmacokinetic study of aprepitant-sulfobutyl ether-β-cyclodextrin complex.Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients.Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics.Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy.Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study.Effects of antioxidant herbs on chemotherapy-induced nausea and vomiting in a rat-pica model.
P2860
Q28258863-043B7505-1DCC-4F9C-8993-2AFF9D2EBE4EQ28262693-AF1B2E2A-0612-4194-BA89-D076972B5033Q34239808-042B25F5-6B2B-445A-A56A-33580E22C4AFQ35163168-F3733D5C-1123-45E9-B33F-812103036B80Q35345557-A33CF7DA-5B5C-4C70-A256-9B1311595ACCQ35594000-0B77C2D2-D996-4715-9C43-19BAB8CB0EC8Q35594004-9AB5AFE6-3649-4ED5-AAEB-6B772BDA5EE8Q35666500-7CDDB85C-FF1B-4A63-B072-7AF0F1114FF5Q35779340-4A149A50-CAAB-4EB4-9AAE-D9ABF51BF1C8Q35865448-33548058-8D62-4BAC-8E35-19D3521959FBQ35964412-0374C5FE-FB00-4231-877B-38C9A272FDB9Q36276557-D73694DF-714F-445A-88D1-4B3AD27B60D3Q36284018-B77A8241-AC57-4C83-9A18-CA0D6CE40D7BQ36407422-2B1CA62D-F1D4-4264-8675-69E5067F7383Q36823546-D496F8BD-6590-449C-B81E-40AAF40BE8B9Q36843470-06D7770D-986B-490D-87FE-36C50913CCD2Q36909501-2FF2AB60-E36F-480F-B0C5-82CE30765F76Q37316977-6459EFC1-0166-4D6A-97AE-64D1997358C7Q37355479-7D79892F-64FF-43DE-B275-382D1DF56255Q37538937-BD9A9829-2F82-417E-AB9C-5655F0B4F31DQ37677897-A6C13D91-9135-4689-821B-BE4A9BFE5C6EQ37783929-8042F501-6269-4FF3-99F6-D9B8AE141989Q37857329-B893BDE5-EDCB-4EF4-8CB5-A12066B4D52FQ37902946-228AF171-7409-4016-8C40-3CCAE1894B8FQ37982438-7F3916C0-CEC9-474E-BDA0-F46FCA93D258Q38036613-12B7A2A3-3A2B-46EF-9B48-88E2DFB0F5BBQ38208999-7DB67133-06FF-4C7E-9991-D706A1C76E41Q42551206-6523C21B-EFFD-49BD-97F6-ED7B7FA5B22EQ42973034-68207D49-E76A-4FF7-9DC4-E947DEDF0B43Q44062377-51064D36-0BA0-4D9E-8148-D3AC020F3BDCQ44571968-52A2796B-5E7F-4B54-A598-FC613F0684C6Q44925317-AC1E17ED-E727-4242-A5FE-8E02A69346F0Q45077382-8B0F0EFE-BA52-4135-B039-1FF628EB83C5Q46954375-E42100B9-4BEF-4039-8543-15AED6B7C212Q48491599-6920EE7C-5559-4C3B-87C6-E6F19E387BC1Q51239101-C18D6723-4743-4519-A621-6A638CC56D19
P2860
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.
@en
Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.
@nl
type
label
Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.
@en
Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.
@nl
prefLabel
Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.
@en
Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.
@nl
P2093
P1476
Comparison of L-758,298, a pro ...... n of cisplatin-induced emesis.
@en
P2093
Carides AD
Decramer ML
Eldridge K
Reinhardt RR
Schellens JH
P304
P356
10.1016/S0959-8049(00)00416-0
P577
2001-05-01T00:00:00Z